Indeed, our previous study in two mouse models of AD showed a dramatic (50%–70%) decrease in amyloid plaque deposition, glial activation markers, and phosphorylated tau after 12 weeks of treatment with the C5aR1 antagonist PMX205. The gene discussed is C5AR1; the disease is Alzheimer disease.